Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019
Week 96 data from the BRIGHTE study of first-in-class fostemsavir continue to show improvement in virologic suppression and immunologic response
Read more -
IAS 2019: ViiV Healthcare showcasing innovation in HIV science
Data to be presented span the company’s diverse portfolio, challenging the current treatment paradigm and investigating new options to meet the evolving needs of people living w...
Read more -
GSK announces positive headline results in Phase 3 PRIMA study of ZEJULA (niraparib) for patients with ovarian cancer in the first line maintenance setting
Niraparib demonstrates significant improvement in progression free survival for women regardless of their biomarker status
Read more -
ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen
Week 48 results from the TANGO study will be presented this month at 10th International AIDS Society Conference on HIV Science (IAS 2019).
Read more -
GSK welcomes the UK trial of subscription-style payment system for pharma companies to incentivise creation of new antibiotics
GSK welcomes the UK trial of subscription-style payment system for pharma companies to incentivise creation of new antibiotics
Read more -
ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice
The long-acting injectable regimen has been granted Priority Review status by the FDA, with a target approval date set for December 29, 2019
Read more -
GSK announces phase III start for its anti GM-CSF antibody, otilimab, in patients with rheumatoid arthritis (RA)
First phase III programme in RA to include head-to-head comparisons with current treatments across all pivotal studies in a broad range of difficult-to-treat RA patients.
Read more -
ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection
Authorisation based on GEMINI pivotal trials in which Dovato achieved non-inferior efficacy compared to a dolutegravir-based, three-drug regimen through 48 weeks, with no cases ...
Read more -
U.S. Food and Drug Administration accepts GSK’s application for ZEJULA (niraparib) in late stage ovarian cancer with priority review
GlaxoSmithKline plc today announced that TESARO, an oncology-focused business acquired by GSK, submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Adm...
Read more -
GSK joins forces with the University of California to advance genomic research and improve drug discovery
New ‘Laboratory for Genomics Research’ unites CRISPR pioneers with industry expertise to help unravel mysteries of the human genome
Read more -
GSK announces data on anti-BCMA antibody-drug conjugate in patients with relapsed/refractory multiple myeloma to be presented at European Hematology Association (EHA) Congress
GlaxoSmithKline plc today announced new data on belantamab mafodotin (GSK2857916), an investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate, will be pres...
Read more -
Nucala (mepolizumab) gains FDA approval for two new self-administration options
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinject...
Read more -
Nucala (mepolizumab) receives positive CHMP opinion for new self-administration options
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion re...
Read more -
GSK announces approval of Shingrix in China for prevention of shingles in adults aged 50 and over
Shingrix is a recombinant subunit adjuvanted vaccine given intramuscularly in two doses.
Read more -
GSK changes sales representative incentive programme
We are announcing changes to our incentive programme for sales representatives in certain countries.
Read more -
GSK’s strong science prominent at ATS 2019
More than 70 GSK abstracts presented
Read more -
Update on Consumer Healthcare Joint Venture with Pfizer
GlaxoSmithKline plc (LSE/NYSE: GSK) today has announced that the shareholder resolution relating to the transaction between GSK and Pfizer Inc to create a Consumer Healthcare Jo...
Read more -
Phase III CAPTAIN study of Trelegy Ellipta in patients with asthma meets primary endpoint
-
Read more -
GSK delivers sales of £7.7 billion +6% AER, +5% CER
Total EPS 16.8p, +50% AER, +42% CER; Adjusted EPS 30.1p, +22% AER, +18% CER
Read more -
ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV
If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV.
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
